NASDAQ:SNY - Nasdaq - US80105N1054 - ADR - Currency: USD
51.98
-0.53 (-1.01%)
The current stock price of SNY is 51.98 USD. In the past month the price decreased by -0.65%. In the past year, price increased by 7.09%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 51.87 | 676.59B | ||
JNJ | JOHNSON & JOHNSON | 15.22 | 367.98B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.24 | 299.26B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.69B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.93 | 218.30B | ||
MRK | MERCK & CO. INC. | 9.96 | 195.22B | ||
PFE | PFIZER INC | 7.26 | 132.58B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.38 | 95.34B | ||
GSK | GSK PLC-SPON ADR | 7.02 | 78.23B | ||
ZTS | ZOETIS INC | 27.01 | 72.38B | ||
HLN | HALEON PLC-ADR | 22.73 | 50.23B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 26.49 | 45.51B |
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008 FR
CEO: Paul Hudson
Employees: 84587
Phone: 33153774000
The current stock price of SNY is 51.98 USD. The price decreased by -1.01% in the last trading session.
The exchange symbol of SANOFI-ADR is SNY and it is listed on the Nasdaq exchange.
SNY stock is listed on the Nasdaq exchange.
29 analysts have analysed SNY and the average price target is 67.56 USD. This implies a price increase of 29.98% is expected in the next year compared to the current price of 51.98. Check the SANOFI-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SANOFI-ADR (SNY) has a market capitalization of 126.50B USD. This makes SNY a Large Cap stock.
SANOFI-ADR (SNY) currently has 84587 employees.
SANOFI-ADR (SNY) has a support level at 49.66 and a resistance level at 52.42. Check the full technical report for a detailed analysis of SNY support and resistance levels.
The Revenue of SANOFI-ADR (SNY) is expected to grow by 1.53% in the next year. Check the estimates tab for more information on the SNY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SANOFI-ADR (SNY) has a dividend yield of 4.18%. The yearly dividend amount is currently 2.17. Check the full fundamental report for a detailed analysis of SNY dividend history, reliability and sustainability.
SANOFI-ADR (SNY) will report earnings on 2025-07-31, before the market open.
The PE ratio for SANOFI-ADR (SNY) is 13.57. This is based on the reported non-GAAP earnings per share of 3.83 and the current share price of 51.98 USD. Check the full fundamental report for a full analysis of the valuation metrics for SNY.
The outstanding short interest for SANOFI-ADR (SNY) is 0.16% of its float. Check the ownership tab for more information on the SNY short interest.
ChartMill assigns a technical rating of 2 / 10 to SNY. When comparing the yearly performance of all stocks, SNY turns out to be only a medium performer in the overall market: it outperformed 60.53% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to SNY. While SNY belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months SNY reported a non-GAAP Earnings per Share(EPS) of 3.83. The EPS decreased by -12.99% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 12.97% | ||
ROA | 9% | ||
ROE | 15.37% | ||
Debt/Equity | 0.17 |
ChartMill assigns a Buy % Consensus number of 80% to SNY. The Buy consensus is the average rating of analysts ratings from 29 analysts.
For the next year, analysts expect an EPS growth of 8.37% and a revenue growth 1.53% for SNY